Oversubscribed share issue
The Board of Immunicum AB decided on February 12, 2013 to issue new shares bringing in a total of SEK 21,4 million. The new share issue was oversubscribed. The capital that was raised will enable the completion of the ongoing clinical phase I/II-study in renal cancer, as well as the phase I/II-study in liver cancer that the Company plans.
The share issue will provide the Company with up to 890 new shareholders and the listing process on NASDAQ OMX First North may therefore also be completed according to plan with the preliminary first trading day on April 22:nd.